Racial Inequities in Receiving Neoadjuvant Treatment in Patients With Pancreatic Cancer Are Associated With Worse Outcomes in Louisiana
Journal of Surgical Oncology · 2025
DOI: 10.1002/jso.27901 ↗At a glance
Journal article in Journal of Surgical Oncology, 2025. Written by Hannah R Malinosky and 9 co-authors. Institution: Department of Surgery, Division of Surgical Oncology, Louisiana State University (LSU) Health, New Orleans, Louisiana, USA. Major MEDLINE topics: Carcinoma, Pancreatic Ductal, Healthcare Disparities, Neoadjuvant Therapy, Pancreatic Neoplasms. Cited 2 times so far (Crossref); 16 references. Funded by: The authors received no specific funding for this work..
Abstract (original language)
Background
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer‐related deaths. In recent years, the approach to managing this malignancy has evolved toward embracing neoadjuvant treatment (NAT), backed by studies reporting its survival benefit. This study aimed to identify factors that contribute to disparities in NAT utilization and their impact on outcomes in patients with PDAC who underwent resection in Louisiana.
Methods
Data on diagnosed PDAC cases were obtained from the Louisiana Tumor Registry between 2000 and 2020. We conducted multivariable logistic regression to adjust for potential confounding factors in assessing the covariate relationships with NAT use. Multivariate Cox regression analysis was performed to determine which factors were associated with survival. Chained multiple imputation was performed on covariates with missing data in multivariable regressions.
Results
The study encompassed 2121 patients who underwent resection for PDAC. Upon controlling for potential confounding variables, Black patients were on average 5.7% less likely to receive NAT than their White counterparts (ATE = 5.7, aOR= 0.56, 95% CI = 0.40−0.80, p = 0.001). After adjustment for confounding factors, there was a significant decrease in the risk of overall death for patients who received NAT (aHR = 0.82, 95% CI = 0.71−0.94, p = 0.006). There was no significant interaction between race and NAT for the risk of death.
Conclusion
Black patients with PDAC were less likely to receive NAT before resection in Louisiana. Overall survival improved in patients who underwent NAT. These differences were independent of insurance status and poverty zip codes, and future investigations should identify modifiable barriers to access and receipt of NAT in patients with PDAC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Surgery, Division of Surgical Oncology, Louisiana State University (LSU) Health, New Orleans, Louisiana, USA.
- Department of Interdisciplinary Oncology, Louisiana State University (LSU) Health School of Medicine, New Orleans, Louisiana, USA.
- LSU-LCMC Cancer Center, New Orleans, Louisiana, USA.
- Louisiana Tumor Registry, New Orleans, Louisiana, USA.
- Department of Surgery, Louisiana State University (LSU) Health, Baton Rouge, Louisiana, USA.
Funding
- The authors received no specific funding for this work.
Cite
APA
Malinosky, H. R., Chapple, A. G., Hargis, M., Wu, X. C., Efishat, M. A., Lyons, J., Watson, J. C., Maluccio, M., Nfonsam, V. N., & Moaven, O. (2025). Racial Inequities in Receiving Neoadjuvant Treatment in Patients With Pancreatic Cancer Are Associated With Worse Outcomes in Louisiana. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27901
Vancouver
Malinosky HR, Chapple AG, Hargis M, Wu XC, Efishat MA, Lyons J, et al. Racial Inequities in Receiving Neoadjuvant Treatment in Patients With Pancreatic Cancer Are Associated With Worse Outcomes in Louisiana. Journal of Surgical Oncology. 2025. doi:10.1002/jso.27901
BibTeX
@article{Malinosky2025,
author = {Malinosky, Hannah R and Chapple, Andrew G and Hargis, McKenzie and Wu, Xiao-Cheng and Efishat, Mohammad Al and Lyons, John and Watson, James C and Maluccio, Mary and Nfonsam, Valentine N and Moaven, Omeed},
title = {Racial Inequities in Receiving Neoadjuvant Treatment in Patients With Pancreatic Cancer Are Associated With Worse Outcomes in Louisiana},
journal = {Journal of Surgical Oncology},
year = {2025},
doi = {10.1002/jso.27901}
}
EUVIMED